Home » Newsletters » BioWorld

BioWorld

Nov. 5, 1991

View Archived Issues

SOMATIX GETS OPTIONS FOR CATHETER LICENSES

ECOGEN GETS EQUITY INVESTMENT

APPLIED BIOSCIENCE ACQUIRES PHARMACO

FDA APPROVES TRIALS OF PSORIASIS DRUG

IMMUNOGEN RETURNS TO OFFERINGS WELL

GENZYME GETS DIAGNOSTIC ENZYME BUSINESS

PET CANCER TREATMENT CONDITIONALLY APPROVED

IMMUNE TO FILE IND FOR ARTHRITIS VACCINE

GENTA FILES 'QUIET' IPO

BIOTECH BUBBLE MAY BE READY TO BURST

SPHINX INKS FOUR-YEAR DEAL WITH LILLY

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...